Abstract

A range of public health measures have been implemented to suppress local transmission of coronavirus disease 2019 (COVID-19) in Shenzhen. We examined the effect of these measures on the prevalence of respiratory pathogens in children. Clinical and respiratory pathogen data were collected for routine care from hospitalized children with acute respiratory infections in Shenzhen Children’s Hospital from July 2018 to January 2022. Nasopharyngeal swabs were collected and respiratory pathogens were detected using standardized clinical diagnostics as part of routine care. Data were analyzed to describe the effects of COVID-19 prevention procedures on other common pathogens. A total of 56,325 children under 14 years of age were hospitalized with an acute respiratory infection during the study period, 33,909 were tested from July 2018 to January 2020 (pre-lockdown), 1168 from February 2020 to May 2020 (lockdown) and 21,248 from July 2020 to January 2022 (post-lockdown). We observed a 37.3% decline of routine care in respiratory infection associated hospital admission in the 19 months’ post-lockdown vs. the 19 months’ pre-lockdown. There were 99.4%, 16.0% and 1.26% reductions measured for Mycoplasma pneumoniae, influenza virus A and adenovirus, respectively. However, a 118.7% and 75.8% rise was found for respiratory syncytial virus (RSV) and human para-influenza virus (HPIV) during the 19 months’ post-lockdown in comparison to the pre-pandemic period. The detection of RSV especially increased in toddlers after the lockdown. Lockdown measures during the COVID-19 pandemic led to a significant reduction of Mycoplasma pneumoniae, influenza virus A and adenovirus infection. In contrast, RSV and HPIV infection increased.

Details

Title
Lockdown measures during the COVID-19 pandemic strongly impacted the circulation of respiratory pathogens in Southern China
Author
Wang, Heping 1 ; Zheng, Yuejie 2 ; de Jonge, Marien I. 3 ; Wang, Rongjun 2 ; Verhagen, Lilly M. 4 ; Chen, Yunsheng 2 ; Li, Li 2 ; Xu, Zhi 5 ; Wang, Wenjian 2 

 Shenzhen Children’s Hospital, Shenzhen, China (GRID:grid.452787.b) (ISNI:0000 0004 1806 5224); Radboud University Medical Center, Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud Center for Infectious Diseases, Nijmegen, The Netherlands (GRID:grid.10417.33) (ISNI:0000 0004 0444 9382) 
 Shenzhen Children’s Hospital, Shenzhen, China (GRID:grid.452787.b) (ISNI:0000 0004 1806 5224) 
 Radboud University Medical Center, Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud Center for Infectious Diseases, Nijmegen, The Netherlands (GRID:grid.10417.33) (ISNI:0000 0004 0444 9382) 
 Radboud University Medical Center, Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud Center for Infectious Diseases, Nijmegen, The Netherlands (GRID:grid.10417.33) (ISNI:0000 0004 0444 9382); Amalia Children’s Hospital, Radboud University Medical Center, Department of Pediatric Infectious Diseases and Immunology, Nijmegen, The Netherlands (GRID:grid.461578.9) 
 Ningbo Health Gene Technologies Co., Ltd, Ningbo, China (GRID:grid.459830.3) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2722750544
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.